- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07480603
Pilot Study on a New Self Adjustable Glaucoma Drainage Device (eV-SEN)
Pilot Study eyeValve
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Sali, Senegal
- SwissVisio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women aged 18 to 90 years.
Diagnosis of primary open-angle glaucoma meeting the following criteria:
- Intraocular pressure (IOP) not controlled by at least one (1) or more classes of topical IOP-lowering medications, and
- Eye without visual acuity.
Patients must be able to understand the study requirements and provide written informed consent.
Patients must be willing to follow study instructions, agree to comply with all study procedures, and be able to attend all scheduled follow-up visits for at least 6 months after surgery.
Exclusion Criteria:
- Previous filtering surgery, secondary glaucoma, severe systemic disease, pregnancy, breastfeeding, or inability to understand or provide informed consent.
Pregnant or breastfeeding women, or women of childbearing potential who are not willing to use a medically acceptable method of contraception from the screening visit until the 12-month follow-up visit.
Known or suspected allergy or hypersensitivity to any component of the device (e.g., silicone).
Current participation, or participation within the last 30 days (from the screening visit), in another investigational drug or interventional device clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: eyeValve
Patient treated with the device
|
Implantation of a self adjustable glaucoma drainage device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety
Time Frame: 3 months
|
Type and rate of complications post-surgery
|
3 months
|
|
IOP reduction
Time Frame: Baseline versus every visit, up to 1 year
|
IOP reduction by >20%
|
Baseline versus every visit, up to 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- eV-7007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Hospices Civils de LyonRecruitingOpen-angle Glaucoma | Glaucoma Eye | Pigmentary Glaucoma | Closed-Angle Glaucoma | Pseudo Exfoliative SyndromeFrance
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Isfahan University of Medical SciencesActive, not recruitingAngle Closure Glaucoma | Glaucoma EyeIran
-
University of MiamiAbbVieRecruitingOcular Hypertension | Glaucoma | Open-Angle Glaucoma | Glaucoma SuspectUnited States
-
Ngoc Nguyen Inc.Alcon ResearchNot yet recruitingGlaucoma | Glaucoma, Open Angle | Open Angle Glaucoma (OAG) | Normal Tension Glaucoma (NTG)United States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Dr. Kaweh MansouriEnrolling by invitationGlaucoma, Angle-Closure | Surgery | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma; Drugs | Glaucoma, Pigmentary | Glaucoma Secondary | Glaucoma Open-Angle | Glaucoma Congenital | Glaucoma CapsulareSwitzerland
-
iSTAR MedicalInternational Drug Development InstituteActive, not recruitingGlaucoma, Open-Angle Glaucoma EyeIndia, Panama